[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Wall St Engine [@wallstengine](/creator/twitter/wallstengine) on x 71.4K followers Created: 2025-07-09 10:18:25 UTC Evercore ISI Upgrades $DOCS to Outperform from In Line, Raises PT to $XX from $XX Analyst comments: "Overall, we see DOCS as prudently setting FY26 guidance in a conservative spot. We see the PoC/Formulary business as likely to grow at least mid-double digits (vs. ~100% in FY25) in FY26 to $140+ million, supported by recent channel checks. This would allow the remaining Pharma business to grow ~2% and still hit the current midpoint of the company’s current revenue guide of $619-631 million (assuming ~2% growth in health systems/hospital revenue). In addition, we see Pharma revenue (~$535 million in FY26) supported by continued strong GLP-1-related spending, which we estimate will contribute ~$60 million to revenue (up double digits year-over-year) and should help to offset a potential weaker-than-expected upsell season (with further upside to come in out years from the oral launch). Our current FY26 revenue estimate of $XXX million is on the high end of management’s current guidance range and could have 5%+ upside with continued market stability. On the EBITDA side, DOCS has an enviable model with very high incremental EBITDA margins when revenue outperforms expectations, which could create $25+ million of upside to EBITDA (current Evercore ISI estimate of $XXX million) in FY26 from the above-mentioned revenue outperformance, which would support upside to valuation and current consensus (also ~$340 million)." Analyst: Elizabeth Anderson XXXXX engagements  **Related Topics** [digits](/topic/digits) [$docs](/topic/$docs) [Post Link](https://x.com/wallstengine/status/1942891081332588932)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Wall St Engine @wallstengine on x 71.4K followers
Created: 2025-07-09 10:18:25 UTC
Evercore ISI Upgrades $DOCS to Outperform from In Line, Raises PT to $XX from $XX
Analyst comments: "Overall, we see DOCS as prudently setting FY26 guidance in a conservative spot. We see the PoC/Formulary business as likely to grow at least mid-double digits (vs. ~100% in FY25) in FY26 to $140+ million, supported by recent channel checks. This would allow the remaining Pharma business to grow ~2% and still hit the current midpoint of the company’s current revenue guide of $619-631 million (assuming ~2% growth in health systems/hospital revenue).
In addition, we see Pharma revenue (~$535 million in FY26) supported by continued strong GLP-1-related spending, which we estimate will contribute ~$60 million to revenue (up double digits year-over-year) and should help to offset a potential weaker-than-expected upsell season (with further upside to come in out years from the oral launch). Our current FY26 revenue estimate of $XXX million is on the high end of management’s current guidance range and could have 5%+ upside with continued market stability.
On the EBITDA side, DOCS has an enviable model with very high incremental EBITDA margins when revenue outperforms expectations, which could create $25+ million of upside to EBITDA (current Evercore ISI estimate of $XXX million) in FY26 from the above-mentioned revenue outperformance, which would support upside to valuation and current consensus (also ~$340 million)."
Analyst: Elizabeth Anderson
XXXXX engagements
